Kura Oncology to Present at J.P. Morgan Healthcare Conference
03 janv. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma
02 déc. 2018 12h00 HE
|
Kura Oncology, Inc.
– Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL – – AITL and other PTCL patients with high CXCL12 expression experienced 50% ORR and 90%...
Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
28 nov. 2018 07h30 HE
|
Kura Oncology, Inc.
– AITL patent expands protection for tipifarnib, provides exclusivity in U.S. to 2037 – – Prospective data from AITL and CXCL12+ cohorts in Phase 2 trial of tipifarnib in PTCL upcoming at ASH 2018 – ...
Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors
08 nov. 2018 07h30 HE
|
Kura Oncology, Inc.
Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a...
Kura Oncology to Participate in Two Upcoming Investor Conferences
06 nov. 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update
05 nov. 2018 16h05 HE
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway – – Encouraging preliminary clinical activity observed in HRAS mutant SCC cohort – – Preliminary data from AITL and...
Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas
05 nov. 2018 07h30 HE
|
Kura Oncology, Inc.
– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE)...
Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting
01 nov. 2018 09h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Third Quarter 2018 Financial Results
29 oct. 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
22 oct. 2018 08h45 HE
|
Kura Oncology, Inc.
– Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization greater than six months – – One additional HNSCC...